Phathom Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 197.72 million compared to USD 143.88 million a year ago. Basic loss per share from continuing operations was USD 5.05 compared to USD 3.89 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.69 USD | +2.69% | +5.84% | +17.09% |
May. 09 | Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.09% | 609M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- PHAT Stock
- News Phathom Pharmaceuticals, Inc.
- Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022